Investment firms raise price targets and maintain positive ratings for Crinetics Pharmaceuticals.

Robert W. Baird raised its price target for Crinetics Pharmaceuticals (NASDAQ:CRNX) from $52.00 to $62.00, and Morgan Stanley increased its target from $50.00 to $70.00, both with an overweight rating. JMP Securities maintained a market outperform rating and set a $80.00 target price, while Cantor Fitzgerald reiterated an overweight rating with a $65.00 price objective. HC Wainwright reissued a buy rating with a $60.00 target price.